Brookline Cap M Weighs in on CervoMed FY2025 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Investment analysts at Brookline Cap M issued their FY2025 earnings per share (EPS) estimates for shares of CervoMed in a research note issued to investors on Tuesday, February 3rd. Brookline Cap M analyst F. Ahmed expects that the company will post earnings per share of ($2.65) for the year. Brookline Cap M currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Brookline Cap M also issued estimates for CervoMed’s Q4 2025 earnings at ($0.78) EPS.

A number of other research analysts have also recently weighed in on the stock. Brookline Capital Acquisition upgraded shares of CervoMed to a “strong-buy” rating in a report on Tuesday. Zacks Research upgraded shares of CervoMed from a “strong sell” rating to a “hold” rating in a research note on Monday, January 12th. D. Boral Capital reaffirmed a “buy” rating and set a $31.00 price objective on shares of CervoMed in a research report on Tuesday, December 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of CervoMed in a report on Wednesday, January 21st. Finally, Roth Mkm set a $20.00 target price on CervoMed and gave the stock a “buy” rating in a research note on Friday, October 17th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, CervoMed currently has an average rating of “Moderate Buy” and a consensus price target of $22.17.

CervoMed Trading Up 15.4%

CRVO opened at $5.31 on Friday. The firm has a market cap of $49.12 million, a price-to-earnings ratio of -1.83 and a beta of -0.82. The stock’s 50-day moving average price is $7.36 and its 200 day moving average price is $8.14. CervoMed has a 12-month low of $1.92 and a 12-month high of $16.94.

CervoMed (NASDAQ:CRVO) last announced its earnings results on Friday, November 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). CervoMed had a negative net margin of 415.27% and a negative return on equity of 76.78%. The firm had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $1.43 million.

Hedge Funds Weigh In On CervoMed

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in CervoMed in the 2nd quarter valued at about $414,000. Citadel Advisors LLC acquired a new position in CervoMed in the 3rd quarter valued at about $247,000. Savvy Advisors Inc. acquired a new stake in shares of CervoMed during the 3rd quarter worth about $210,000. AQR Capital Management LLC acquired a new position in shares of CervoMed in the first quarter valued at approximately $227,000. Finally, Two Sigma Investments LP acquired a new stake in CervoMed during the third quarter worth approximately $138,000. 25.15% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO John J. Alam acquired 10,793 shares of the company’s stock in a transaction on Monday, November 17th. The shares were bought at an average price of $8.46 per share, with a total value of $91,308.78. Following the completion of the acquisition, the chief executive officer owned 12,500 shares in the company, valued at $105,750. This trade represents a 632.28% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sylvie Gregoire purchased 10,807 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were purchased at an average price of $8.46 per share, for a total transaction of $91,427.22. Following the purchase, the director directly owned 12,500 shares in the company, valued at $105,750. The trade was a 638.33% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have purchased 92,000 shares of company stock valued at $737,723. 35.40% of the stock is owned by corporate insiders.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.